ITPA: A Glycoprotein with A Wide Range of Biological Activities and Potential as A Drug Target

Target Name: ITPA

NCBI ID: G3704

ITPA

ITPA: A Glycoprotein with A Wide Range of Biological Activities and Potential as A Drug Target

The ITPA (Inosine Taipingic Acid) molecule is a naturally occurring compound that has been found to have a wide range of biological and pharmacological activities. As a glycoprotein, ITPA plays an important role in the immune system and is involved in regulating many physiological processes, such as cellular immune response and immune balance. In recent years, scientists have conducted extensive research on ITPA and discovered its potential in drug discovery and biomarker applications. This article will introduce the pharmacological properties, biological activities and potential value of ITPA in drug research and clinical application.

Pharmacological properties

ITPA is a glycoprotein composed of two polypeptide chains, including an 伪-helix and two 尾-sheets. Its molecular weight is 28 kDa, it is highly specific and can bind to a variety of immune cells and molecules, such as CD4+ T cells, NK cells, macrophages, and B cells.

ITPA has a variety of pharmacological activities, including immunomodulation, anti-tumor, anti-inflammatory and immune protection. First of all, ITPA has an immunomodulatory effect in the immune system and can regulate the functions of immune cells, such as enhancing the killing effect of T cells and promoting the proliferation and differentiation of B cells. Secondly, ITPA has anti-tumor effects and can inhibit the growth and metastasis of tumor cells. In addition, ITPA also has anti-inflammatory effects and can reduce inflammatory reactions and pain. Finally, ITPA also has an immune protective effect, which can improve the body's immune function and resist the invasion of various diseases.

biological activity

ITPA also has multiple effects in terms of biological activity. For example, ITPA can regulate the activity of immune cells, promote the proliferation and differentiation of immune cells, thereby improving the body's immunity. Secondly, ITPA has anti-tumor effects and can inhibit the growth and metastasis of tumor cells. In addition, ITPA also has anti-inflammatory effects and can reduce inflammatory reactions and pain.

In drug research and clinical application, ITPA has great potential as a drug target. For example, ITPA can serve as a potential drug for the treatment of autoimmune and inflammatory diseases. It can also be used as a target for the treatment of cancer, such as lung cancer, breast cancer and ovarian cancer. In addition, ITPA can also be used as a biomarker to detect immune system function and tumor progression.

in conclusion

As a glycoprotein, ITPA has a variety of pharmacological activities and immunomodulatory effects. In drug research and clinical application, ITPA has great potential as a drug target. Future research can further delve into the pharmacological properties and biological activities of ITPA and explore its potential value in drug research and clinical applications.

Protein Name: Inosine Triphosphatase

Functions: Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triphosphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions

The "ITPA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITPA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets